共 50 条
Personalized medicine in psychiatry: problems and promises
被引:173
|作者:
Ozomaro, Uzoezi
[1
]
Wahlestedt, Claes
[1
,2
,3
]
Nemeroff, Charles B.
[1
,2
,3
]
机构:
[1] Univ Miami, Leonard M Miller Sch Med, Miami, FL 33136 USA
[2] Univ Miami, Miller Sch Med, Hussman Inst Human Genom, Ctr Therapeut Innovat, Miami, FL 33136 USA
[3] Univ Miami, Leonard M Miller Sch Med, Dept Psychiat & Behav Sci, Miami, FL USA
来源:
BMC MEDICINE
|
2013年
/
11卷
基金:
美国医疗保健研究与质量局;
美国国家卫生研究院;
关键词:
Major depressive disorder;
Schizophrenia;
Personalized medicine;
Psychiatric hereditability;
Epigenetics;
Environmental factors;
Endophenotypes;
Pharmacogenomics;
Neuroimaging genetics;
CORTICOTROPIN-RELEASING-FACTOR;
SEROTONIN TRANSPORTER GENE;
GENOME-WIDE ASSOCIATION;
INDUCED WEIGHT-GAIN;
SINGLE NUCLEOTIDE POLYMORPHISM;
MAJOR DEPRESSIVE DISORDER;
FAMILY-BASED ASSOCIATION;
5-HT2A RECEPTOR GENE;
CLOZAPINE-INDUCED AGRANULOCYTOSIS;
ABNORMAL INVOLUNTARY MOVEMENTS;
D O I:
10.1186/1741-7015-11-132
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
The central theme of personalized medicine is the premise that an individual's unique physiologic characteristics play a significant role in both disease vulnerability and in response to specific therapies. The major goals of personalized medicine are therefore to predict an individual's susceptibility to developing an illness, achieve accurate diagnosis, and optimize the most efficient and favorable response to treatment. The goal of achieving personalized medicine in psychiatry is a laudable one, because its attainment should be associated with a marked reduction in morbidity and mortality. In this review, we summarize an illustrative selection of studies that are laying the foundation towards personalizing medicine in major depressive disorder, bipolar disorder, and schizophrenia. In addition, we present emerging applications that are likely to advance personalized medicine in psychiatry, with an emphasis on novel biomarkers and neuroimaging.
引用
收藏
页数:35
相关论文